Cargando…

Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?

In the last 20 years there has been a huge increase in the number of novel drugs for cancer treatment. Most of them exploit their ability to target specific oncogenic mutations in the tumors (targeted therapies–TT), while others target the immune-checkpoint inhibitor molecules (ICI) or the epigeneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Damele, Laura, Ottonello, Selene, Mingari, Maria Cristina, Pietra, Gabriella, Vitale, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226262/
https://www.ncbi.nlm.nih.gov/pubmed/32218226
http://dx.doi.org/10.3390/cancers12040774
_version_ 1783534249626828800
author Damele, Laura
Ottonello, Selene
Mingari, Maria Cristina
Pietra, Gabriella
Vitale, Chiara
author_facet Damele, Laura
Ottonello, Selene
Mingari, Maria Cristina
Pietra, Gabriella
Vitale, Chiara
author_sort Damele, Laura
collection PubMed
description In the last 20 years there has been a huge increase in the number of novel drugs for cancer treatment. Most of them exploit their ability to target specific oncogenic mutations in the tumors (targeted therapies–TT), while others target the immune-checkpoint inhibitor molecules (ICI) or the epigenetic DNA modifications. Among them, TT are the longest established drugs exploited against a wide spectrum of both solid and hematological tumors, often with reasonable costs and good efficacy as compared to other innovative therapies (i.e., ICI). Although they have greatly improved the treatment of cancer patients and their survival, patients often relapse or develop drug-resistance, leading to the impossibility to eradicate the disease. The outcome of TT has been often correlated with their ability to affect not only tumor cells, but also the repertoire of immune cells and their ability to interact with cancer cells. Thus, the possibility to create novel synergies among drugs an immunotherapy prompted scientists and physicians to deeply characterize the effects of TT on immune cells both by in-vitro and by ex-vivo analyses. In this context, NK cells may represent a key issue, since they have been shown to exert a potent anti-tumor activity, both against hematological malignancies and solid tumors. In the present review we will discuss most recent ex-vivo analyses that clarify the effect of TT treatment on patient’s NK cells comparing them with clinical outcome and previous in-vitro data.
format Online
Article
Text
id pubmed-7226262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72262622020-05-18 Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance? Damele, Laura Ottonello, Selene Mingari, Maria Cristina Pietra, Gabriella Vitale, Chiara Cancers (Basel) Review In the last 20 years there has been a huge increase in the number of novel drugs for cancer treatment. Most of them exploit their ability to target specific oncogenic mutations in the tumors (targeted therapies–TT), while others target the immune-checkpoint inhibitor molecules (ICI) or the epigenetic DNA modifications. Among them, TT are the longest established drugs exploited against a wide spectrum of both solid and hematological tumors, often with reasonable costs and good efficacy as compared to other innovative therapies (i.e., ICI). Although they have greatly improved the treatment of cancer patients and their survival, patients often relapse or develop drug-resistance, leading to the impossibility to eradicate the disease. The outcome of TT has been often correlated with their ability to affect not only tumor cells, but also the repertoire of immune cells and their ability to interact with cancer cells. Thus, the possibility to create novel synergies among drugs an immunotherapy prompted scientists and physicians to deeply characterize the effects of TT on immune cells both by in-vitro and by ex-vivo analyses. In this context, NK cells may represent a key issue, since they have been shown to exert a potent anti-tumor activity, both against hematological malignancies and solid tumors. In the present review we will discuss most recent ex-vivo analyses that clarify the effect of TT treatment on patient’s NK cells comparing them with clinical outcome and previous in-vitro data. MDPI 2020-03-25 /pmc/articles/PMC7226262/ /pubmed/32218226 http://dx.doi.org/10.3390/cancers12040774 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Damele, Laura
Ottonello, Selene
Mingari, Maria Cristina
Pietra, Gabriella
Vitale, Chiara
Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
title Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
title_full Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
title_fullStr Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
title_full_unstemmed Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
title_short Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
title_sort targeted therapies: friends or foes for patient’s nk cell-mediated tumor immune-surveillance?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226262/
https://www.ncbi.nlm.nih.gov/pubmed/32218226
http://dx.doi.org/10.3390/cancers12040774
work_keys_str_mv AT damelelaura targetedtherapiesfriendsorfoesforpatientsnkcellmediatedtumorimmunesurveillance
AT ottonelloselene targetedtherapiesfriendsorfoesforpatientsnkcellmediatedtumorimmunesurveillance
AT mingarimariacristina targetedtherapiesfriendsorfoesforpatientsnkcellmediatedtumorimmunesurveillance
AT pietragabriella targetedtherapiesfriendsorfoesforpatientsnkcellmediatedtumorimmunesurveillance
AT vitalechiara targetedtherapiesfriendsorfoesforpatientsnkcellmediatedtumorimmunesurveillance